Benzinga · Sep 17, 2026
BTIG Reiterates Buy on Neuronetics, Maintains $6 Price Target
BTIG analyst Sam Eiber reiterates Neuronetics (NASDAQ:STIM) with a Buy and maintains $6 price target.
ST
NASDAQ · STIM
Neuronetics, Inc.
Healthcare · Medical - Diagnostics & Research
$2.21
Up+$0.01 (+0.45%)
Updated Oct 7, 2026, 8:51 AM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 94.17M
- P/E ratio
- -2.1
- Dividend yield
- 0.00%
- 52-week range
- $0.80 – $3.44
- Volume
- 771.88K
- Avg. volume
- 1.57M
Price performance · STIM
STIM price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
STIM closed at $2.21 after 21 trading sessions, down 24.57% for the selected period.
- Last close
- $2.21
- Period change
- -24.57%
- Period low
- $2.16
- Period high
- $3.04
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $2.22 | $2.28 | $2.19 | $2.21 | 771.88K |
| Oct 5, 2026 | $2.14 | $2.275 | $2.125 | $2.20 | 812.06K |
| Oct 2, 2026 | $2.23 | $2.26 | $2.12 | $2.16 | 1.27M |
| Oct 1, 2026 | $2.38 | $2.38 | $2.20 | $2.22 | 1.31M |
| Sep 30, 2026 | $2.362 | $2.419 | $2.34 | $2.34 | 624.79K |
| Sep 29, 2026 | $2.55 | $2.5655 | $2.33 | $2.36 | 1.27M |
| Sep 28, 2026 | $2.70 | $2.71 | $2.54 | $2.555 | 958.94K |
| Sep 25, 2026 | $2.81 | $2.84 | $2.74 | $2.74 | 477.8K |
| Sep 24, 2026 | $2.86 | $2.885 | $2.76 | $2.82 | 590.47K |
| Sep 23, 2026 | $2.88 | $2.92 | $2.83 | $2.88 | 779.71K |
| Sep 22, 2026 | $2.75 | $2.97 | $2.73 | $2.91 | 809.56K |
| Sep 21, 2026 | $2.88 | $2.905 | $2.80 | $2.85 | 627.96K |
| Sep 18, 2026 | $2.92 | $3.0404 | $2.85 | $2.90 | 1.12M |
| Sep 17, 2026 | $2.80 | $2.98 | $2.7902 | $2.97 | 1.04M |
| Sep 16, 2026 | $2.80 | $2.856 | $2.63 | $2.76 | 1.55M |
| Sep 15, 2026 | $2.88 | $2.9677 | $2.66 | $2.80 | 1.64M |
| Sep 14, 2026 | $3.03 | $3.25 | $2.8701 | $2.905 | 7.21M |
| Sep 11, 2026 | $3.10 | $3.1454 | $3.015 | $3.03 | 749.11K |
| Sep 10, 2026 | $2.99 | $3.08 | $2.90 | $3.01 | 640.79K |
| Sep 9, 2026 | $2.91 | $3.115 | $2.85 | $3.04 | 1.42M |
| Sep 8, 2026 | $2.85 | $3.01 | $2.82 | $2.93 | 1.43M |
Latest STIM news
The latest Smart Investors Daily articles mentioning STIM.
Stock researchCompany · Overview
Company
Market Activity
Research & News
STIM research
Overview
Company profile and research snapshot.
Company profile
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $8.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 17, 2026 | BTIG | Buy | — |
| Sep 11, 2026 | B. Riley Securities | Buy | — |
| Sep 9, 2026 | BTIG | Buy | — |
| Aug 11, 2026 | BTIG | Buy | — |
| Jul 20, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 11, 2026
B. Riley Securities Initiates Coverage On Neuronetics with Buy Rating, Announces Price Target of $5
B. Riley Securities analyst Madison El-Saadi initiates coverage on Neuronetics (NASDAQ:STIM) with a Buy rating and announces Price Target of $5.
Benzinga · Sep 9, 2026
BTIG Reiterates Buy on Neuronetics, Maintains $6 Price Target
BTIG analyst Sam Eiber reiterates Neuronetics (NASDAQ:STIM) with a Buy and maintains $6 price target.
Yahoo · Sep 8, 2026
NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System
First-of-Its-Kind Integration Connects TrakStar and AdvancedMD, Delivering TMS Care Across Clinical, Operational, and Billing WorkflowsMALVERN, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the integration of its TrakStar® practice management platform with AdvancedMD, a leading c
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
